Spacer length effects on in vitro imaging and surface accessibility of fluorescent inhibitors of prostate specific membrane antigen

https://doi.org/10.1016/j.bmcl.2011.09.115Get rights and content

Abstract

Prostate-specific membrane antigen (PSMA), a type II transmembrane protein, has been becoming an active target for imaging and therapeutic applications for prostate cancer. Recently, the development of its various chemical inhibitor scaffolds has been explored to serve as carriers for therapeutic or diagnostic payloads targeted to PSMA-positive tumor cells. However, there have been few efforts to definitively determine the optimal length of linker between PSMA inhibitor cores and their payload molecules with regard to the affinity to PSMA and in vitro performance. In our present model study, three spacer-length varied fluorescent inhibitors (FAM-CTT-54, FAM-X-CTT-54 and FAM-PEG8-CTT-54) were synthesized, and further enzymatic inhibition studies displayed linker length-dependent changes in: inhibitory potency (IC50 = 0.41 nM, 0.35 nM, 1.93 nM), modes of binding (reversible, slowly reversible, irreversible), respectively. Furthermore, cell-labeling imaging revealed the spacer length-related change of fluorescence intensity (FAM-X-CTT-54 > FAM-PEG8-CTT-54 > FAM-CTT-54). These results suggest that selection of linkers and their lengths will be important considerations in the development of next-generation prostate tumor-targeted imaging probes and therapeutic agents that specifically home to PSMA on tumor cells.

Graphical abstract

A series of spacer-varied imaging probes were synthesized and evaluated, which exhibited spacer length-dependent effects on inhibitory potency, mode of inhibition, and fluorescence imaging of prostate cancer cells.

  1. Download : Download full-size image

Section snippets

Acknowledgments

The authors extend their gratitude for technical assistance to G. Helms and W. Hiscox at the WSU Center for NMR Spectroscopy, as well as C. Davitt and V. Lynch-Holm at the WSU Franceschi Microscopy and Imaging Center. This work was supported in part by the Washington State Life Sciences Discovery Fund (LSDF 08-01 2374880) and the National Institutes of Health (5R01CA140617-02).

References and notes (37)

  • S.S. Chang et al.

    Urology

    (2001)
  • D.W. Wone et al.

    Bioorg. Med. Chem.

    (2006)
  • T. Tsukamoto et al.

    Drug Discovery Today

    (2007)
  • L.Y. Wu et al.

    Bioorg. Med. Chem.

    (2007)
  • T. Liu et al.

    Bioorg. Med. Chem. Lett.

    (2010)
  • T. Liu et al.

    Cancer Lett.

    (2010)
  • M. Wang et al.

    Pharmacol Res.

    (2010)
  • C. Barinka et al.

    J. Mol. Biol.

    (2008)
  • G. Kada et al.

    Biochim. Biophys. Acta

    (1999)
  • W.D. Bedzyk et al.

    Biochim. Biophys. Acta

    (1992)
  • D.J. Bacich et al.

    Mamm. Genome.

    (2001)
  • S.S. Chang et al.

    Clin. Cancer Res.

    (1999)
  • L.S. Grauer et al.

    Cancer Res.

    (1998)
  • R.E. Carter et al.

    Proc. Natl. Acad. Sci. U.S.A.

    (1996)
  • J.T. Pinto et al.

    Clin. Cancer Res.

    (1996)
  • J.R. Mesters et al.

    Acta Crystallogr., Sect. D

    (2007)
  • M.I. Davis et al.

    Proc. Natl. Acad. Sci. U.S.A.

    (2005)
  • J.R. Mesters et al.

    EMBO J.

    (2006)
  • Cited by (36)

    • PSMA-targeted SMART molecules outfitted with SN38

      2024, Bioorganic and Medicinal Chemistry Letters
    • Synthesis and evaluation of a multifunctional probe with a high affinity for prostate-specific membrane antigen (PSMA) and bone

      2022, Nuclear Medicine and Biology
      Citation Excerpt :

      These findings indicate that a strategy of detecting bone metastases by introducing oligo-aspartic acid into tumor-targeting peptides cannot be adapted in all cases. However, the previous studies of the structure-activity relationships of PSMA reported that the pharmacophore of PSMA ligands binds the funnel-shaped cavity binding site of PSMA [32], and a payload site, such as a diagnostic RI and a therapeutic RI, could be located far from the binding site without affecting the affinity for PSMA by introducing a sufficient linker length [33]. An oligo-aspartic acid would also constitute a spacer molecule to place the Ga-DOTA complex distal to the KuE pharmacophore, which may account for the similar binding affinity between 2 and PSMA-617 for PSMA.

    • Design, synthesis, radiolabeling and biological evaluation of new urea-based peptides targeting prostate specific membrane antigen

      2020, Bioorganic Chemistry
      Citation Excerpt :

      As anticipated, the Glu-GABA-Asp also exhibited an appropriate interaction with PSMA catalytic site. Moreover, an electron-rich and bulky spacer showed the best results presumably due to good electrostatical interaction with arginine residues in PSMA active site, providing the optimal distance (20 A°) between pharmacophore and chelating agent to occupy the pharmacophore into glutamate pocket and consequently easy labeling of HYNIC core [50]. One of the aspects highlighted in synthesis procedure of urea-based peptides is that both isocyanate intermediate and urea bond were formed on solid phase.

    • PSMA PET and Radionuclide Therapy in Prostate Cancer

      2016, Seminars in Nuclear Medicine
      Citation Excerpt :

      DOTA is capable of binding several isotopes including 68Ga, 177Lu, and 90Y. The molecule’s binding affinity is remarkably sensitive to small changes in the linker, and changes in the linker also influences the pharmacokinetic properties of the agent.29 Thus, PSMA DKFZ 617 is a true theranostic inhibitor capable of both I&T using different radioisotopes.

    • A fluorophore-tagged RGD peptide to control endothelial cell adhesion to micropatterned surfaces

      2014, Biomaterials
      Citation Excerpt :

      The presence of different spacer arms between a solid support and affinity binding molecules can affect the interactions between these molecules and their binding partners. The effect of the spacer length has been well-studied in the context of microarray technologies [37,38] and the targeting of nanoparticles to desired tissues [39,40]. The conformation of the RGD sequence and the residues surrounding this sequence impact its integrin binding affinity [41] and its effect on cell adhesion [42].

    View all citing articles on Scopus
    View full text